Last mentioned: Mar 20, 2026
ASH Annual Meeting
Curis targets presentation of initial proof-of-concept data for the CLL study.
Torrid Store Closures
Target date for an additional 30 store closures by Torrid to reach savings goals.
Q4 Earnings Release
Curis, Torrid, Caleres, and Lands' End all report Q4 2025 results.
PIPE Financing
Curis secured initial $20.2M in PIPE proceeds to fund oncology pipeline development.
Erivedge Wind-down
Royalties from Erivedge began winding down, prompting the strategic sale to Oberland.
Recent Q4 2025 earnings from Torrid, Caleres, and Lands' End reveal a retail landscape defined by aggressive inventory management and the looming impact of import tariffs. While Lands' End and Caleres saw top-line growth through acquisitions and marketplace expansion, Torrid continues a significant restructuring involving over 150 store closures to stabilize its bottom line.
Curis (CRIS) has successfully pivoted to a clinical-stage oncology focus, securing a cash runway into 2027 through a strategic asset sale and PIPE financing. Meanwhile, broader retail earnings from Torrid and Caleres reveal significant margin pressures from tariffs, signaling a complex macro environment for healthcare supply chains.